Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and why this meeting is so important in this space. The combination of ...

Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The company revealed its results at this week’s Conference on Retroviruses ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...

An expert on the intersection of HIV and menopause, Bridgette J. Picou, LVN, ACLPN, The Well Project, explains the importance ...

A Save Our Sciences rally March 10 at the Yerba Buena Gardens in the city's South of Market neighborhood – adjacent to the Moscone Center, where the Conference on Retroviruses and Opportunistic ...

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

Spotlight reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections. Several new ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI ...

researchers said at the Conference on Retroviruses and Opportunistic Infections. SAN FRANCISCO — Researchers here described how they were able to safely and ethically enroll adolescents in a ...